Subcutaneous immunotherapy injections work the same way as their intravenous counterparts — by changing or enhancing a person’s immune responses to cancer. Immunotherapy for cancer is a broad category ...

Subcutaneous (subQ or SQ) injections are shots given in the fatty tissue layer (subcutaneous fat) under your skin. Your skin has many layers, and the subcutaneous layer is beneath the epidermis and ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved atezolizumab and hyaluronidase-tqjs for subcutaneous injection. The agent (Tecentriq Hybreza, ...

The FDA approves a new subcutaneous formulation of amivantamab, enhancing treatment for advanced lung cancer with reduced administration time and improved safety.

PD-1 inhibitors belong to a class of medications known as immune checkpoint inhibitors, which have become an important part of many modern cancer treatment plans. PD-1 inhibitors work by helping the ...

FDA approved pembrolizumab and berahyaluronidase alfa-pmph for patients aged 12 and older with solid tumors. Study MK-3475A-D77 showed a 45% ORR in subcutaneous administration for treatment-naïve ...

Dr. Eric K. Singhi discusses the benefit of subcutaneous immunotherapy following the FDA approval of subcutaneous Opdivo for patients with solid tumors. On Dec. 27, 2024, the Food and Drug ...

The subcutaneous formulation of Opdivo provides a convenient alternative to intravenous administration for patients with solid tumors, maintaining efficacy and safety. The CHECKMATE-67T trial ...